Omega-3 fatty acids improve quality of life, outcomes in cancer
the ONA take:
According to a new study published online ahead of print in the Journal of Parenteral and Enteral Nutrition (JPEN), researchers at the University Hospitals of Leicester in the United Kingdom have found that the addition of omega-3 fatty acids to anti-cancer medications may improve quality of life and treatment outcomes in patients with cancer.
For the study, researchers enrolled 150 patients with advanced pancreatic cancer. Participants received gemcitabine 1,000 mg weekly followed by up to 100 g of omega-3 rich lipid emulsion for 3 weeks followed by 1 rest week. Patients received up to six cycles until disease progression, unacceptable toxicity, patient request, or death.
Results showed that patients who received omega-3 fatty acids experienced an improvement in response activity and disease stabilization rates, a reduction in liver metastases volume, and improved quality of life.
The findings suggest that further investigation is warranted to evaluate the addition of omega-3 fatty acids with a chemotherapy agent in a randomized phase III trial.
Addition of omega-3 fatty acids to anti-cancer medications may improve quality of life and treatment outcomes in patients with cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|